{"organizations": [], "uuid": "7c97ba2b5abe0f85474c13b7db7764c60256e331", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-janssen-announces-darzalex-us-fda/brief-janssen-announces-darzalex-u-s-fda-approval-for-patients-with-multiple-myeloma-idUSASC0A0B2", "country": "US", "domain_rank": 408, "title": "BRIEF-Janssen Announces Darzalex U.S. FDA Approval For Patients With Multiple Myeloma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T05:46:00.000+03:00", "replies_count": 0, "uuid": "7c97ba2b5abe0f85474c13b7db7764c60256e331"}, "author": "", "url": "https://www.reuters.com/article/brief-janssen-announces-darzalex-us-fda/brief-janssen-announces-darzalex-u-s-fda-approval-for-patients-with-multiple-myeloma-idUSASC0A0B2", "ord_in_thread": 0, "title": "BRIEF-Janssen Announces Darzalex U.S. FDA Approval For Patients With Multiple Myeloma", "locations": [], "entities": {"persons": [{"name": "janssen", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "darzalex u.s. fda", "sentiment": "negative"}, {"name": "brief-janssen announces darzalex u.s. fda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "multiple myeloma reuters", "sentiment": "none"}, {"name": "janssen pharma", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 7 (Reuters) -\n* JANSSEN ANNOUNCES DARZALEXÂ® (DARATUMUMAB) U.S. FDA APPROVAL FOR NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE\n* JANSSEN PHARMA - FDA APPROVAL OF DARZALEX IN COMBINATION WITH BORTEZOMIB, MELPHALAN AND PREDNISONE MARKS ITS FIFTH INDICATION IN MULTIPLE MYELOMA Source text for Eikon:\nOur ", "external_links": [], "published": "2018-05-08T05:46:00.000+03:00", "crawled": "2018-05-08T06:00:25.014+03:00", "highlightTitle": ""}